Articles By Nelly Ziade

Magnifying glass

GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis

By Nelly Ziade

The “Difficult” framework has now reached PsA. At EULAR 2025, two independent definitions were presented: one by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and another by EULAR. This short review explores the similarities and differences between these definitions and discusses their potential implications for clinical practice and research, especially for the increasingly perplexed rheumatologist.

Read Article
psor.elb_.jpg

Predicting Psoriatic Arthritis in Psoriasis: How Close Are We?

By Nelly Ziade

Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis (PsO), and diagnostic delays are associated with worse prognosis, making early detection crucial. At EULAR 2025, several studies highlighted progress in prediction strategies. Here's my review of three of them.

Read Article
diversity together global leadership

Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors

By Nelly Ziade

The concept of Difficult-to-Manage (D2M) axial spondyloarthritis (axSpA) is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. This unified definition has stimulated a wave of new research globally, with multiple studies analysing D2M axSpA in diverse clinical cohorts.

Read Article
Profile picture for user Nelly Ziade
  • Nelly Ziade

  • Dr. Nelly Ziade is the head of the rheumatology department at Saint-Joseph University and Hotel-Dieu de France Hospital in Beirut, Lebanon. She is currently an associate professor of rheumatology and was elected a Fellow of the Royal College of Physicians of London. Dr. Ziade is the president of the Lebanese Society of Rheumatology, president of the ArLAR Research Group (the ARCH), a member of the French Society of Rheumatology, and a full ASAS member. Dr. Ziade’s main clinical research interests target epidemiology, spondyloarthritis, rheumatoid arthritis, patient education and digital health.

×